Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.

about

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.

Item

http://www.wikidata.org/entity/Q47678852

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@en

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@nl

type

Item

label

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@en

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@nl

prefLabel

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@en

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@nl

P1476

Trastuzumab in Combination wit ...... ective Multicenter AGEO Study.

@en

P2093

Astrid Pozet

http://www.w3.org/2001/XMLSchema#string

Aziz Zaanan

http://www.w3.org/2001/XMLSchema#string

David Tougeron

http://www.w3.org/2001/XMLSchema#string

Emilie Soularue

http://www.w3.org/2001/XMLSchema#string

Florence Leroy

http://www.w3.org/2001/XMLSchema#string

Juliette Palle

http://www.w3.org/2001/XMLSchema#string

Pascal Artru

http://www.w3.org/2001/XMLSchema#string

Samy Louafi

http://www.w3.org/2001/XMLSchema#string

Sylvain Manfredi

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv

HER2-positive gastric cancer.

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

P2888

s11523-017-0531-4

P31

scholarly article

P356

10.1007/S11523-017-0531-4

http://www.w3.org/2001/XMLSchema#string

P50

Julien Taïeb

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29090377

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma